May 1, 2009 · Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder. Recently, …

Mouse strains differ in their baseline characteristics but macroscopic IMQ responses are consistent. Mouse back skin was treated with 62.5 mg Aldara™ (5% IMQ) or a non-toxic …

One of the most widely approved psoriasis-like animal models is the imiquimod (IMQ)-induced mouse model. This representation mimics various aspects of the complex cutaneous …

May 1, 2009 · Topical application of imiquimod (IMQ), a TLR7/8 ligand and potent immune activator, can induce and exacerbate psoriasis, a chronic inflammatory skin disorder. Recently, …

Jan 28, 2021 · By consecutive 7-day-treatment with 42.5 mg of IMQ on female C57BL/6 mice, distinct psoriatic lesion was induced on the back skin with the severity peaked on day 5; …

However, digoxin treatment increased the IMQ-induced back skin thickening at day 6 (1.13 vs. 0.94 mm, p<0.01; Fig. 1C), and increased erythema and scaling on the back skin (sum score …

The most commonly used model for the disease is the Imiquimod-induced skin inflammation model (IMQ-model). In the IMQ model, Aldara cream (containing 5% IMQ) is applied topically …

Imiquimod (IMQ) produces a cutaneous phenotype in mice frequently studied as an acute model of human psoriasis. IMQ is a Toll-like Receptor (TLR7) agonist that can be applied to mouse …

JAX offers preclinical imiquimod-induced psoriasis mouse models as a rapid screening approach for candidate psoriatic therapies. Imiquimod (IMQ) is a toll-like receptor agonist that acts as an …

To induce disease, imiquimod is applied to the ear and back of mice daily for 5 days (Days 0 to 4). Treatment may be prophylactic, or therapeutic, usually starting 2 days after initial imiquimod …